Neurology prior auth for MS medications: what your team needs to know right now

If you work in a neurology practice or handle RCM for one, you already know that prior authorizations for multiple sclerosis medications are among the most labor-intensive, documentation-heavy requests in the specialty. Drugs like Ocrevus, Kesimpta, Mavenclad, Tysabri, and the newer high-efficacy agents can run $80,000–$100,000+ annually per patient. Payers know the stakes, and their PA requirements reflect that. As of fall 2026, shifts in payer behavior and formulary management are making these auths more demanding, and if your team isn't prepared, you'll spend a lot of time chasing denials that were preventable.

What's changed in MS prior auth this year

Over the past 12 to 18 months, several major commercial payers and PBMs have quietly tightened step therapy requirements for MS disease-modifying therapies. What used to be a relatively straightforward process for established patients is now triggering re-authorization requirements mid-therapy, particularly when patients switch plans or when employers change their pharmacy benefit contracts.

What's showing up more frequently in 2026:

• Stricter step therapy enforcement. Even for patients already stable on a high-efficacy agent, some payers now require documented failure of a lower-tier injectable (interferon beta or glatiramer acetate) before approving newer oral or infused therapies.


• More granular MRI requirements. Payers want recent imaging, within 12 months in many cases, and "recent" is being interpreted more literally during re-auths.


• Annual re-authorization instead of multi-year approvals. This has become standard across most commercial plans, which means your team is re-fighting the same battles every 12 months.


• Specialty pharmacy channel restrictions. Payers increasingly mandate specific specialty pharmacies. If the PA doesn't specify the approved dispenser correctly, you'll get a rejection that looks clinical but is purely administrative.

Medicare Advantage plans have added another layer. Many now follow commercial-style step therapy protocols that traditional Medicare wouldn't have required, which catches practices off guard when a patient ages into an MA plan.

Building a documentation package that actually holds up

Most denials are won or lost before they happen. The difference between a first-submission approval and a two-week appeals fight usually comes down to whether your documentation package anticipated the payer's specific criteria.

For MS medications, your PA submission should routinely include:

• A complete treatment history. Not just the current medication, but every DMT the patient has ever been on, why they stopped (relapse, intolerance, side effects), and what the clinical response was.


• Current neurological exam findings. EDSS score if your neurologist documents it, along with cognitive and functional status notes.


• MRI reports. Both the narrative and key images if your portal allows it. Don't limit it to the most recent scan; include comparative imaging that shows disease activity over time.


• Lab results relevant to the specific drug. JC virus antibody index for Tysabri, lymphocyte counts for Mavenclad, B-cell depletion monitoring for Ocrevus and Kesimpta.


• A clear physician attestation. A narrative statement from the neurologist explaining why this medication for this patient at this time. Generic templated letters get flagged.

One thing that's easy to overlook: if your patient tried and failed an interferon or glatiramer acetate in the past, even years ago, document that explicitly. Payers use step therapy as a denial reason, but they can't enforce it if the patient already completed the step. That history needs to be front and center in the submission.

Handling the step therapy problem

Step therapy for MS is genuinely contentious. Clinical guidelines from the American Academy of Neurology and the National MS Society increasingly support early high-efficacy therapy for certain patients, particularly those with aggressive or rapidly evolving disease. Payers aren't always aligned with that clinical consensus.

If you're facing a step therapy denial for a patient your neurologist believes needs a high-efficacy DMT from the start, here's a workable path:

• Request a peer-to-peer immediately. Don't wait for the formal appeal timeline to run out. Neurologist-to-neurologist conversations move faster than written appeals in most cases.


• Cite the exception criteria specifically. Most payers have built-in exceptions for step therapy when there's a documented contraindication, prior failure, or clinical urgency. Find those criteria in the plan's coverage policy and write directly to them.


• Use published clinical evidence. The TREAT-MS and OPTIMUM trials, among others, provide real-world data supporting early high-efficacy treatment. Your appeal letter should cite these, not just assert "medically necessary."


• Document urgency carefully. Two or more relapses in the past year, or imaging showing significant new lesion burden, is an urgency argument. Make it explicitly.

Many practices are now using AI-powered appeal letter tools to draft these arguments faster, pulling in relevant clinical literature and structuring the argument around the specific denial reason code. That doesn't replace the clinical judgment of your neurologist, but it can cut the time your billing team spends staring at a blank document.

Re-authorization: don't get caught off guard

The annual re-auth cycle for MS medications looks manageable on paper and becomes a crisis in practice. With a panel of 50 or more MS patients on specialty medications, you could easily have five to ten re-auth deadlines in a single month.

Set up a tracking system, whether that's a field in your EHR, a shared spreadsheet, or your practice management software, that flags re-auth due dates at least 60 days out. That's not excessive. Some payers take 14 to 21 days to process even non-urgent requests, and a medication gap while you're waiting can mean a relapse with real consequences for the patient.

A few practical notes on re-auths:

• Always pull the current coverage policy before submitting. Formulary tier placements and step therapy requirements change at annual benefit resets.


• Confirm the specialty pharmacy assignment hasn't changed, especially for patients on MA plans.


• If a patient's insurance changed since the last auth, treat it as a brand-new submission, not a renewal.

Keep your process current

MS prior auth isn't getting simpler. The practices that handle it best aren't necessarily the ones with the largest billing departments. They're the ones with solid documentation habits, proactive tracking, and a clear escalation path when something gets denied.

Start with your tracking system. Know your deadlines. Build your documentation templates around what payers are actually asking for in 2026, not what they asked for three years ago. When you get a denial, respond fast and respond specifically; generic appeals rarely work for high-cost specialty drugs.

Your neurologists are doing the clinical work. Your job is to make sure the payer doesn't interrupt it.